NEWSBRIEF: Hemispherx Biopharma Inc. is till trying to move toward approval for Ampligen as a chronic fatigue syndrome treatment. The company says it has given new preclinical information to the FDA.
When the FDA announced in December that it was not approving Ampligen, it made recommendations to the company about what was needed to improve the drug's chances of approval down the road. Hemispherx says the data it has just submitted should sufficiently address some of the FDA's concerns.
Ampligen is currently not approved for any use in the US, but some doctors are prescribing it for their chronic fatigue syndrome patients through a special program.
- Learn more: Ampligen Profile
In related news, Hemispherx has given an unrestricted grant to the International Association for Chronic Fatigue Syndrome to assist the organization with research, advocacy and its effort to establish guidelines for treating chronic fatigue syndrome.
Learn more or join the conversation!
NEWSLETTER | FORUM | BIO | TWITTER | FACEBOOK
Shamefully, the scam continues. Ampligen will never be approved for CFS without completely new controlled trials. That will never happen.
Carter belong in jail…my opinion. He lied to us for 20 years…and to investors.